Several immunomodulating treatments of MS were shown to induce moderate reductions in the serum levels of NF-L.6 It has been hypothesized that this is probably related to the suppression of inflammation and of new relapses, which results in the reduction of neuronal damage. This evidence concerns the gene NEFL and myeloid sarcoma.